Duchenne muscular dystrophy
Conditions
Interventions
Group A:Body weight 50kg: ARNI 97/103 mg/24h oral administration Bid
Group B:ACEI 0.2 mg/kg/24h orally administered Bid
Sponsors
West China Second University Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
6 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Written informed consent from the patient and/or legal guardian as required by the district or IRB; 2. Duchenne muscular dystrophy confirmed by genetic testing or muscle biopsy immunohistochemical testing; 3. The LVEF determined by CMR at the time of screening or within 1 month before randomization was >50%,and the CMR assessment was LGE positive; 4. The baseline status can be used to complete the cardiac magnetic resonance examination, and the baseline image quality meets the requirements for the evaluation and measurement of LGE volume, the main therapeutic effect evaluation index; 5. Aged >6 years and regularly treated with glucocorticoids for more than 6 months; He has not been regularly treated with ACEI/ARB drugs for a long time.
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications and allergies to the use of ACEI/ARB/ sacubicyl valsartan, and allergic to magnetic resonance gadolinium contrast agents; 2. 30 days prior to screening exposure to any clinical trial drug (whether for DMD or not), (without limiting other drugs related to this study, such as BB, spironolactone, etc., to be corrected for statistical analysis); 3. There are arrhythmias or severe liver, kidney and lung diseases that require antiarrhythmic treatment; 4. Patients with other heart diseases, such as structural heart disease, cardiomyopathy, valvular heart disease, ischemic heart disease, etc; 5. Any other reason for which the investigator determines that the subject is unable to participate fully in the study and complete the study, including failure to comply with study procedures and treatments or any other related medical history or mental illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ?LGE volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| ?LVEF;?GCS;?ECV;?GLS;? TnI;? NT-pro-BNP; | — |
Countries
China
Contacts
Public ContactHuayan Xu
West China Second University Hospital, Sichuan University
Outcome results
None listed